BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 29866872)

  • 1. Primary Fungal Prophylaxis in Hematological Malignancy: a Network Meta-Analysis of Randomized Controlled Trials.
    Lee CH; Lin C; Ho CL; Lin JC
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Antifungal Prophylaxis Drugs in Patients With Hematological Disease or Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Network Meta-analysis.
    Wang J; Zhou M; Xu JY; Zhou RF; Chen B; Wan Y
    JAMA Netw Open; 2020 Oct; 3(10):e2017652. PubMed ID: 33030550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second- versus first-generation azoles for antifungal prophylaxis in hematology patients: a systematic review and meta-analysis.
    Ping B; Zhu Y; Gao Y; Yue C; Wu B
    Ann Hematol; 2013 Jun; 92(6):831-9. PubMed ID: 23455400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
    Ziakas PD; Kourbeti IS; Mylonakis E
    Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A network meta-analysis of primary prophylaxis for invasive fungal infection in haematological patients.
    Leonart LP; Tonin FS; Ferreira VL; Penteado STS; Wiens A; Motta FA; Pontarolo R
    J Clin Pharm Ther; 2017 Oct; 42(5):530-538. PubMed ID: 28620958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Network meta-analysis of triazole, polyene, and echinocandin antifungal agents in invasive fungal infection prophylaxis in patients with hematological malignancies.
    Zeng H; Wu Z; Yu B; Wang B; Wu C; Wu J; Lai J; Gao X; Chen J
    BMC Cancer; 2021 Apr; 21(1):404. PubMed ID: 33853560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survey of antifungal prophylaxis and fungal diagnostic tests employed in malignant haematology and haemopoietic stem cell transplantation (HSCT) in Australia and New Zealand.
    van Hal SJ; Gilroy NM; Morrissey CO; Worth LJ; Szer J; Tam CS; Chen SC; Thursky KA; Slavin MA
    Intern Med J; 2014 Dec; 44(12b):1277-82. PubMed ID: 25482740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.
    Ullmann AJ; Lipton JH; Vesole DH; Chandrasekar P; Langston A; Tarantolo SR; Greinix H; Morais de Azevedo W; Reddy V; Boparai N; Pedicone L; Patino H; Durrant S
    N Engl J Med; 2007 Jan; 356(4):335-47. PubMed ID: 17251530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: a systematic review.
    Pechlivanoglou P; Le HH; Daenen S; Snowden JA; Postma MJ
    J Antimicrob Chemother; 2014 Jan; 69(1):1-11. PubMed ID: 23975736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
    Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
    Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs.
    Wang JF; Xue Y; Zhu XB; Fan H
    Eur J Clin Microbiol Infect Dis; 2015 Apr; 34(4):651-9. PubMed ID: 25502737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of posaconazole antifungal prophylaxis in reducing the incidence of invasive aspergillosis in patients with acute myeloid leukemia.
    Le Clech L; Uguen M; Quinio D; Nevez G; Couturier MA; Ianotto JC; Berthou C; Guillerm G; Le Bars H; Payan C; Narbonne V; Baron R; Saliou P
    Curr Res Transl Med; 2020 Jan; 68(1):23-28. PubMed ID: 31787568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of posaconazole for the prevention of invasive fungal infections in immunocompromised patients: a systematic review with meta-analysis and trial sequential analysis.
    Wong TY; Loo YS; Veettil SK; Wong PS; Divya G; Ching SM; Menon RK
    Sci Rep; 2020 Sep; 10(1):14575. PubMed ID: 32884060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posaconazole: an extended-spectrum triazole antifungal agent.
    Schiller DS; Fung HB
    Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compare the efficacy of antifungal agents as primary therapy for invasive aspergillosis: a network meta-analysis.
    Liu A; Xiong L; Wang L; Zhuang H; Gan X; Zou M; Wang X
    BMC Infect Dis; 2024 Jun; 24(1):581. PubMed ID: 38867163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials.
    Vardakas KZ; Michalopoulos A; Falagas ME
    Br J Haematol; 2005 Oct; 131(1):22-8. PubMed ID: 16173959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of micafungin versus extensive azoles in the prevention and treatment of invasive fungal infections for neutropenia patients with hematological malignancies: A meta-analysis of randomized controlled trials.
    Lee CH; Lin JC; Ho CL; Sun M; Yen WT; Lin C
    PLoS One; 2017; 12(7):e0180050. PubMed ID: 28700646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients.
    Vehreschild MJ; von Bergwelt-Baildon M; Tran L; Shimabukuro-Vornhagen A; Wisplinghoff H; Bangard C; Cornely OA; Vehreschild JJ
    Eur J Haematol; 2014 Nov; 93(5):400-6. PubMed ID: 24798021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014.
    Fleming S; Yannakou CK; Haeusler GM; Clark J; Grigg A; Heath CH; Bajel A; van Hal SJ; Chen SC; Milliken ST; Morrissey CO; Tam CS; Szer J; Weinkove R; Slavin MA
    Intern Med J; 2014 Dec; 44(12b):1283-97. PubMed ID: 25482741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
    Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D
    N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.